USMJ Details $20 Million Marijuana and CBD Sales Growth Plan In Shareholder Update
March 30 2022 - 11:50AM
InvestorsHub NewsWire
Dallas, TX --
March 30, 2022 -- InvestorsHub NewsWire -- North American Cannabis
Holdings, Inc. (USOTC:
USMJ) today published a shareholder update with details on the
company’s plans for adding $20 million in sales on top of the
company’s growing sales from its expanding ecommerce
business. The update from CEO Steven Rash is included in its
entirety below:
Dear
Shareholders:
USMJ’s launch
into 2022 following the business refresh organized at the end of
last year has gone better than we could have
imagined.
Our relaunch
of the EVERx CBD Sports Nutrition Beverage acquired from Puration,
Inc. (USOTC:
PURA) has us taking measure of our original sales forecasts as
we now see an even bigger opportunity, and New York’s new adult use
marijuana law is a welcome and potentially game changing
surprise.
Adult Use Marijuana Business
Development
In February,
New York passed a new law to provide provisional marijuana
cultivation licenses to existing hemp
businesses.
USMJ has a subsidiary that has been
growing hemp for CBD for the past four years. The subsidiary
has received an invitation from the New York Office of Cannabis
Management (OCM) to apply for the provisional adult-use cannabis
license.
We are
planning on partnering with an experienced marijuana cultivator and
distributor from out of state. The intent of the partnership
is to accelerate our learning curve to fully optimize the 2-year
window afforded in the new New York
law.
We have
engaged in negotiations with two experienced out of state marijuana
cultivators. In the course of our negotiations, we have
learned that under the license afforded by New York, USMJ could
produce adult use marijuana generating from $5 million to $11
million per year in revenue. Given the 2-year window and
start up time needed, we are optimistic USMJ could generate
approximately $15 million in revenue from an adult use marijuana
program within the 2-year window. We are certainly intent on
building a program that would continue beyond the 2-year window,
but only targeting revenue potential within the 2-year window at
this time.
EVERx CBD Sports Nutrition
Beverage
The EVERx
formula and packaging has been updated. The new formula and
packaging was recently introduced at Arnold Schwarzenegger’s
Arnold Sports Festival. The new formula and packaging
were well received.
EVERx has
historic retail distribution channels established by PURA prior to
USMJ’s acquisition. The recent Arnold Sports Festival participation
open new distribution opportunities. The overall distribution
opportunity for EVERx, in light of the reaction at the Arnold, is
bigger than anticipated. Accordingly, we recently initiated a
new EVERx production order with our co-packer partner Alkame
Holdings, Inc. (USOTC:
ALKM).
Considering
PURA’s EVERx distribution history and taking into account the new
opportunities coming out of the Arnold, we believe it is possible
to see EVERx generate $5 million in revenue over the next two
years.
In addition to
our ongoing efforts to expand our ecommerce business, the adult use
marijuana opportunity and EVERx relaunch, we believe, have the
potential to generate $20 million in revenue over the next two
years.
I look forward
to keeping you up to date on our quickly developing new adult use
marijuana and EVERx
opportunities.
Sincerely,
Steven
Rash
CEO
USMJ
USMJ is
founded on the core belief that cannabis makes people's lives
better. Cannabis can fight disease, improve wellness and do so in
an environmentally sustainable manner. North American Cannabis
Holdings is dedicated to finding the best possible applications for
cannabis to serve consumers. The Company operates USMJ.com and is
dedicated to Ongoing Cannabis Consumer Product Development that it
can incubate into Future
Spin-offs.
Visit the
company’s ecommerce site now and bookmark the site to watch for
more coming announcements and updates:
www.USMJ.com
Contact:
USMJ
Steven Rash
info@aciconglomerated.com
+1 (800)
861-1350
Disclaimer/Safe
Harbor: This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that Alkame will achieve significant sales, the failure
to meet schedule or performance requirements of the Company's
contracts, the Company's liquidity position, the Company's ability
to obtain new contracts, the emergence of competitors with greater
financial resources and the impact of competitive pricing. In the
light of these uncertainties, the forward-looking events referred
to in this release might not occur. These statements have not been
evaluated by the Food and Drug Administration. These products are
not intended to diagnose, treat, cure, or prevent any
disease.
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Dec 2023 to Dec 2024